GoAI
Get started
Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc.

HRMY

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$38.15

+$0.08 · +0.21%

Aug 21, 4:00 PM ET

HRMY company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

86

Deep Value

Momentum

58

Neutral

Sentiment

71

Bullish

Risk resilience

67

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jeffrey Dayno
Listed since
Aug 19, 2020
Employees
293

Market position

Day range

Current $38.15

52-week range

Current $38.15

Open
$38.22
Previous close
$38.07
Volume
380.08K
0.45× average
Average volume
847.38K
Average daily volume
Market cap
2.21B USD
Beta
0.91
Market reference 1
50-day average
$36.3038
+5.09% above average
200-day average
$33.8352
+12.75% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.64B USD
P/E (TTM)
12.19×
P/B (TTM)
2.21×
P/S (TTM)
2.3×
EV / EBITDA
6.42×
Earnings yield
7.38%
Free cash flow yield
16.17%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
75.42%
Operating margin
24.03%
Net margin
18.88%
Return on equity
18.24%
Return on assets
12.48%
Return on invested capital
13.90%

Financial health

Debt / equity
0.15×
Current ratio
3.6×
Altman Z-score
5.63
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends89%61%32%4%Gross margin, FY2021: 81.82%Gross margin, FY2022: 80.93%Gross margin, FY2023: 79.17%Gross margin, FY2024: 78.06%Gross margin, FY2025: 77.16%Operating margin, FY2021: 28.66%Operating margin, FY2022: 27.45%Operating margin, FY2023: 32.99%Operating margin, FY2024: 26.70%Operating margin, FY2025: 24.00%Net margin, FY2021: 11.33%Net margin, FY2022: 41.44%Net margin, FY2023: 22.14%Net margin, FY2024: 20.36%Net margin, FY2025: 18.27%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 81.82%. Gross margin FY2022 80.93%. Gross margin FY2023 79.17%. Gross margin FY2024 78.06%. Gross margin FY2025 77.16%. Operating margin FY2021 28.66%. Operating margin FY2022 27.45%. Operating margin FY2023 32.99%. Operating margin FY2024 26.70%. Operating margin FY2025 24.00%. Net margin FY2021 11.33%. Net margin FY2022 41.44%. Net margin FY2023 22.14%. Net margin FY2024 20.36%. Net margin FY2025 18.27%.

Income trends

Revenue

868.45M USD+21.51%

Operating income

208.47M USD+9.25%

Net income

158.69M USD+9.07%
Income trends across reported periods951.84M USD618.3M USD284.75M USD−48.79M USDRevenue, FY2021: 305.44M USDRevenue, FY2022: 437.86M USDRevenue, FY2023: 582.02M USDRevenue, FY2024: 714.73M USDRevenue, FY2025: 868.45M USDOperating income, FY2021: 87.53M USDOperating income, FY2022: 120.19M USDOperating income, FY2023: 192.03M USDOperating income, FY2024: 190.83M USDOperating income, FY2025: 208.47M USDNet income, FY2021: 34.6M USDNet income, FY2022: 181.47M USDNet income, FY2023: 128.85M USDNet income, FY2024: 145.49M USDNet income, FY2025: 158.69M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 305.44M USD. Revenue FY2022 437.86M USD. Revenue FY2023 582.02M USD. Revenue FY2024 714.73M USD. Revenue FY2025 868.45M USD. Operating income FY2021 87.53M USD. Operating income FY2022 120.19M USD. Operating income FY2023 192.03M USD. Operating income FY2024 190.83M USD. Operating income FY2025 208.47M USD. Net income FY2021 34.6M USD. Net income FY2022 181.47M USD. Net income FY2023 128.85M USD. Net income FY2024 145.49M USD. Net income FY2025 158.69M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue868.45M USD714.73M USD582.02M USD437.86M USD305.44M USD
Cost of goods sold198.34M USD156.82M USD121.24M USD83.48M USD55.52M USD
Gross profit670.11M USD557.92M USD460.79M USD354.37M USD249.92M USD
Research and development189.59M USD145.83M USD76.06M USD70.89M USD30.37M USD
Selling, general, and administrative272.05M USD221.27M USD192.69M USD163.3M USD132.03M USD
Operating expenses461.64M USD367.09M USD268.76M USD234.19M USD162.39M USD
Interest income21.92M USD18.54M USD14.73M USD3.13M USD224K USD
Interest expense14.65M USD17.5M USD23.76M USD18.8M USD24.19M USD
Depreciation and amortization25.34M USD24.11M USD24.36M USD23.39M USD18.84M USD
Operating income208.47M USD190.83M USD192.03M USD120.19M USD87.53M USD
Net income158.69M USD145.49M USD128.85M USD181.47M USD34.6M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+39.72%
11 comparable reports
Latest EPS result
1.28
Estimate 0.96 · Beat by 33.89%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.351.010.670.32Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 0.85, estimate 0.74, surprise +14.86%, Beat. Q2 2025, reported May 6, 2025: actual 0.78, estimate 0.59, surprise +32.20%, Beat. Q3 2025, reported Aug 5, 2025: actual 0.68, estimate 0.78, surprise -12.82%, Miss. Q4 2025, reported Nov 4, 2025: actual 0.87, estimate 0.92, surprise -5.43%, Miss. Q1 2026, reported Feb 24, 2026: actual 0.38, estimate 0.84, surprise -54.76%, Miss. Q2 2026, reported May 7, 2026: actual 0.55, estimate 0.76, surprise -27.63%, Miss. Q3 2026, reported Aug 4, 2026: actual 1.28, estimate 0.956, surprise +33.89%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 1.03, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates285.07M247.47M209.86M172.25MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 201.27M USD, estimate 183.21M USD, surprise +9.86%, Beat. Q2 2025, reported May 6, 2025: actual 184.73M USD, estimate 206.05M USD, surprise -10.35%, Miss. Q3 2025, reported Aug 5, 2025: actual 200.49M USD, estimate 220.16M USD, surprise -8.94%, Miss. Q4 2025, reported Nov 4, 2025: actual 239.46M USD, estimate 240.04M USD, surprise -0.24%, Miss. Q1 2026, reported Feb 24, 2026: actual 243.78M USD, estimate 240.33M USD, surprise +1.44%, Beat. Q2 2026, reported May 7, 2026: actual 215.39M USD, estimate 220.84M USD, surprise -2.47%, Miss. Q3 2026, reported Aug 4, 2026: actual 261.28M USD, estimate 250.77M USD, surprise +4.19%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 274.11M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$46.20

21.10% upside
Past 12 months12-month forecastHigh $70.00Average $46.20Low $34.00

Rating distribution

13 ratings
Strong buy00%
Buy862%
Hold323%
Sell215%
Strong sell00%

Recent analyst actions

12 institutions

HRMY news

defenseworld.net

Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY

Aurora Investment Counsel acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange…

Read source
marketbeat.com

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline

Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during…

Read source
defenseworld.net

Harmony Biosciences Holdings, Inc. $HRMY Position Raised by California State Teachers Retirement System

California State Teachers Retirement System raised its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) by 40.9% in the first quarter, according to the company in its most recent 13F filing with…

Read source
zacks.com

4 Healthcare Stocks to Watch as Defensive Demand Strengthens

Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.

Read source
zacks.com

4 Stocks Trading Near 52-Week High With More Upside Potential

Stocks like SNX, AMP, HRMY and NWL are seeing price strength and have a high chance of carrying the momentum forward.

Read source
globenewswire.com

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual…

Read source

HRMY peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding HRMY

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
92.52M
Weight
0.08%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Avantis U.S. Small Cap Value ETF logoAvantis U.S. Small Cap Value ETFAVUV
Market value
91.89M
Weight
0.30%
AUM
31.27B USD
Expense ratio
0.25%
Price / 1D
$126.45+0.66%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
54.85M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
43.73M
Weight
0.05%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
39.9M
Weight
0.02%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
24.67M
Weight
0.38%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
23.05M
Weight
0.05%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Invesco Pharmaceuticals ETF logoInvesco Pharmaceuticals ETFPJP
Market value
16.49M
Weight
3.12%
AUM
535.56M USD
Expense ratio
0.57%
Price / 1D
$130.06+0.91%

Continue in GoAI

Research HRMY

research.disclaimer